组蛋白赖氨酸去甲基化酶KDM2B在癌症中的关键作用。
The critical role of histone lysine demethylase KDM2B in cancer.
作者信息
Yan Meina, Yang Xinxin, Wang Hui, Shao Qixiang
机构信息
Department of Immunology, Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University Zhenjiang 212013, Jiangsu, China.
出版信息
Am J Transl Res. 2018 Aug 15;10(8):2222-2233. eCollection 2018.
Abstract
The discovery of histone demethylases has revealed the dynamic nature of the regulation of histone methylation. KDM2B is an important histone lysine demethylase that removes methyl from H3K36me2 and H3K4me3. It participates in many aspects of normal cellular processes such as cell senescence, cell differentiation and stem cell self-renewal. Recent studies also showed that KDM2B was overexpressed in various types of cancers. This review focuses primarily on the current knowledge of KDM2B and its function in cancer development.
摘要
组蛋白去甲基化酶的发现揭示了组蛋白甲基化调控的动态本质。KDM2B是一种重要的组蛋白赖氨酸去甲基化酶，可去除H3K36me2和H3K4me3上的甲基。它参与正常细胞过程的许多方面，如细胞衰老、细胞分化和干细胞自我更新。最近的研究还表明，KDM2B在各种类型的癌症中过表达。本综述主要关注KDM2B的现有知识及其在癌症发展中的作用。
相似文献
1
The critical role of histone lysine demethylase KDM2B in cancer.组蛋白赖氨酸去甲基化酶KDM2B在癌症中的关键作用。
Am J Transl Res. 2018 Aug 15;10(8):2222-2233. eCollection 2018.
2
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.组蛋白去甲基化酶KDM2B上调组蛋白甲基转移酶EZH2的表达，并在体外和体内促进卵巢癌的进展。
Onco Targets Ther. 2017 Jun 26;10:3131-3144. doi: 10.2147/OTT.S134784. eCollection 2017.
3
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.组蛋白去甲基化酶 KDM2B 通过抑制 p15INK4B、p16INK4A 和 p57KIP2 的转录来促进三阴性乳腺癌的增殖。
Acta Biochim Biophys Sin (Shanghai). 2018 Sep 1;50(9):897-904. doi: 10.1093/abbs/gmy084.
4
Lysine demethylase 2B regulates angiogenesis via Jumonji C dependent suppression of angiogenic transcription factors.赖氨酸去甲基化酶2B通过Jumonji C依赖性抑制血管生成转录因子来调节血管生成。
Biochem Biophys Res Commun. 2022 May 21;605:16-23. doi: 10.1016/j.bbrc.2022.03.054. Epub 2022 Mar 12.
5
KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin-1-mediated chromatin silencing.KDM2B 是一种组蛋白 H3K79 去甲基化酶，通过 SIRT1 介导的染色质沉默诱导转录抑制。
FASEB J. 2018 Oct;32(10):5737-5750. doi: 10.1096/fj.201800242R. Epub 2018 May 15.
6
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.KDM2b/JHDM1b，一种 H3K36me2 特异性去甲基化酶，是急性髓系白血病起始和维持所必需的。
Blood. 2011 Apr 7;117(14):3869-80. doi: 10.1182/blood-2010-10-312736. Epub 2011 Feb 10.
7
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.通过抑制赖氨酸特异性组蛋白去甲基化酶 KDM2B 靶向神经胶质瘤干细胞的存活和化疗耐药性。
Mol Oncol. 2018 Mar;12(3):406-420. doi: 10.1002/1878-0261.12174. Epub 2018 Feb 12.
8
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.组蛋白去甲基化酶KDM2B调节正常和恶性造血过程中的谱系定向分化。
J Clin Invest. 2016 Mar 1;126(3):905-20. doi: 10.1172/JCI84014. Epub 2016 Jan 25.
9
Histone demethylase KDM2B inhibits the chondrogenic differentiation potentials of stem cells from apical papilla.组蛋白去甲基化酶KDM2B抑制根尖乳头干细胞的软骨形成分化潜能。
Int J Clin Exp Med. 2015 Feb 15;8(2):2165-73. eCollection 2015.
10
A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.赖氨酸特异性去甲基化酶1及其在癌症中的作用的全面综述。
Epigenomics. 2017 Aug;9(8):1123-1142. doi: 10.2217/epi-2017-0022. Epub 2017 Jul 12.
引用本文的文献
1
KDM2B regulates stroke injury by modulating OGT-mediated 0-GlcNAcylation of SLC7A11.KDM2B 通过调节 OGT 介导的 SLC7A11 的 0-GlcNAc 化来调节中风损伤。
Commun Biol. 2024 Nov 18;7(1):1530. doi: 10.1038/s42003-024-07251-w.
2
CircMAPK1 induces cell pyroptosis in sepsis-induced lung injury by mediating KDM2B mRNA decay to epigenetically regulate WNK1.环状 MAPK1 通过介导 KDM2B mRNA 的衰减来调控 WNK1 从而诱导脓毒症诱导的肺损伤中的细胞焦亡。
Mol Med. 2024 Sep 19;30(1):155. doi: 10.1186/s10020-024-00932-6.
3
The Wdr5-H3K4me3 Epigenetic Axis Regulates Pancreatic Tumor Immunogenicity and Immune Suppression.Wdr5-H3K4me3 表观遗传学轴调节胰腺肿瘤免疫原性和免疫抑制。
Int J Mol Sci. 2024 Aug 12;25(16):8773. doi: 10.3390/ijms25168773.
4
Epigenetic modulators provide a path to understanding disease and therapeutic opportunity.表观遗传调节剂为理解疾病和提供治疗机会开辟了道路。
Genes Dev. 2024 Jul 19;38(11-12):473-503. doi: 10.1101/gad.351444.123.
5
Role of KDM2B epigenetic factor in regulating calcium signaling in prostate cancer cells.KDM2B表观遗传因子在调节前列腺癌细胞钙信号传导中的作用。
Saudi Pharm J. 2024 Jul;32(7):102109. doi: 10.1016/j.jsps.2024.102109. Epub 2024 May 18.
6
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells.RIPK3 缺陷可阻断 IDH 突变型 AML 细胞中 R-2-羟基戊二酸诱导的坏死性细胞死亡。
Sci Adv. 2024 Apr 19;10(16):eadi1782. doi: 10.1126/sciadv.adi1782. Epub 2024 Apr 17.
7
Sevoflurane Confers Protection Against the Malignant Phenotypes of Lung Cancer Cells via the microRNA-153-3p/HIF1α/KDM2B Axis.七氟醚通过 microRNA-153-3p/HIF1α/KDM2B 轴对肺癌细胞的恶性表型发挥保护作用。
Biochem Genet. 2024 Oct;62(5):3523-3539. doi: 10.1007/s10528-023-10607-2. Epub 2023 Dec 21.
8
The DNA/RNA helicase DHX9 orchestrates the KDM2B-mediated transcriptional regulation of YAP1 in Ewing sarcoma.DNA/RNA解旋酶DHX9在尤因肉瘤中协调KDM2B介导的YAP1转录调控。
Oncogene. 2024 Jan;43(4):225-234. doi: 10.1038/s41388-023-02894-1. Epub 2023 Nov 28.
9
Protective role of estrogen through G-protein coupled receptor 30 in a colitis mouse model.雌激素通过 G 蛋白偶联受体 30 在结肠炎小鼠模型中的保护作用。
Histochem Cell Biol. 2024 Jan;161(1):81-93. doi: 10.1007/s00418-023-02235-z. Epub 2023 Oct 12.
10
H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy.H3K4 三甲基化调控癌症免疫：与免疫疗法联合的有前途的治疗靶点。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2022-005693.
本文引用的文献
1
Cancer stem cells as key drivers of tumour progression.肿瘤干细胞作为肿瘤进展的关键驱动因素。
J Biomed Sci. 2018 Mar 6;25(1):20. doi: 10.1186/s12929-018-0426-4.
2
Kdm2b Regulates Somatic Reprogramming through Variant PRC1 Complex-Dependent Function.Kdm2b 通过依赖于变体 PRC1 复合物的功能来调节体细胞重编程。
Cell Rep. 2017 Nov 21;21(8):2160-2170. doi: 10.1016/j.celrep.2017.10.091.
3
Transcriptional factor OCT4 promotes esophageal cancer metastasis by inducing epithelial-mesenchymal transition through VEGF-C/VEGFR-3 signaling pathway.转录因子OCT4通过VEGF-C/VEGFR-3信号通路诱导上皮-间质转化，从而促进食管癌转移。
Oncotarget. 2017 May 20;8(42):71933-71945. doi: 10.18632/oncotarget.18035. eCollection 2017 Sep 22.
4
Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.具有抗癌活性的赖氨酸（K）特异性去甲基酶 4A 的新型抑制剂。
Invest New Drugs. 2017 Dec;35(6):733-741. doi: 10.1007/s10637-017-0496-2. Epub 2017 Sep 14.
5
Sulfate Aerosols Promote Lung Cancer Metastasis by Epigenetically Regulating the Epithelial-to-Mesenchymal Transition (EMT).硫酸盐气溶胶通过表观遗传调控上皮间质转化（EMT）促进肺癌转移。
Environ Sci Technol. 2017 Oct 3;51(19):11401-11411. doi: 10.1021/acs.est.7b02857. Epub 2017 Sep 13.
6
miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.微小RNA-130b直接靶向ARHGAP1，以驱动尤因肉瘤中转移性细胞分裂周期蛋白42-丝氨酸/苏氨酸蛋白激酶1-激活蛋白1正反馈回路的激活。
Int J Cancer. 2017 Nov 15;141(10):2062-2075. doi: 10.1002/ijc.30909. Epub 2017 Aug 8.
7
Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.组蛋白去甲基化酶KDM1A（LSD1）的新型强效抑制剂，在小鼠早幼粒细胞白血病模型中具有口服活性。
Future Med Chem. 2017 Jul;9(11):1161-1174. doi: 10.4155/fmc-2017-0003. Epub 2017 Jul 19.
8
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.组蛋白去甲基化酶KDM2B上调组蛋白甲基转移酶EZH2的表达，并在体外和体内促进卵巢癌的进展。
Onco Targets Ther. 2017 Jun 26;10:3131-3144. doi: 10.2147/OTT.S134784. eCollection 2017.
9
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.组蛋白去甲基化酶 KDM3A 依赖性 AP-1 转录活性对 PI3K 激活诱导的肝肿瘤发生的影响。
Oncogene. 2017 Nov 9;36(45):6262-6271. doi: 10.1038/onc.2017.222. Epub 2017 Jul 10.
10
Cervical cancer stem cells manifest radioresistance: Association with upregulated AP-1 activity.宫颈癌干细胞表现出放射抵抗性：与 AP-1 活性上调有关。
Sci Rep. 2017 Jul 6;7(1):4781. doi: 10.1038/s41598-017-05162-x.
Zotero 插件